Core Viewpoint - Tonghua Dongbao, one of the domestic insulin "duopoly," has revised its performance forecast, now expecting a net loss of approximately 42.72 million yuan for 2024, marking a significant decline of 103.66% year-on-year [1][4][6]. Financial Performance - The company anticipates a net profit attributable to shareholders of approximately -42.72 million yuan for 2024, a decrease of about 12.11 billion yuan compared to the previous year [4]. - The expected net profit after deducting non-recurring gains and losses is projected to be -9.19 million yuan, down approximately 11.77 billion yuan year-on-year [4]. - This marks the first annual loss for Tonghua Dongbao since 2005, following a profit exceeding 1.1 billion yuan in 2023 [2]. Reasons for Performance Revision - The frequent revisions in performance forecasts are attributed to multiple factors, including the termination of R&D projects, losses from infringement lawsuits, and asset transfers [1][5]. - The company was ordered to pay 61.31 million yuan due to a trademark infringement lawsuit, which has further impacted its profitability [9]. - A significant factor in the loss is the impact of a new round of insulin centralized procurement, leading to price reductions and inventory adjustments by commercial clients, which affected sales revenue [5][10]. R&D and Competitive Position - Tonghua Dongbao's R&D investment has been lower compared to its competitor, Ganli Pharmaceutical, with R&D expenditures from 2021 to 2023 being approximately 3.80 billion yuan, 4.01 billion yuan, and 4.20 billion yuan, representing 11.63%, 14.43%, and 13.66% of revenue, respectively [10]. - In contrast, Ganli Pharmaceutical's R&D investment as a percentage of revenue has consistently exceeded 20% [10]. Shareholder Concerns - The high pledge rate of the major shareholder is a point of concern, with the pledge rate reaching 95.20% [3][12].

Group 1 - The core viewpoint of the articles highlights that Tonghua Dongbao has significantly revised its 2024 annual performance forecast from a profit of approximately 11.64 million yuan to a loss of 42.72 million yuan, marking the second major revision within the year [1][2] - The company attributes the substantial loss to adjustments in deferred tax assets related to subsidiary R&D project transfers and the recognition of losses from prepayments made to SAADOCIA for commercialization rights [1] - The frequent revisions and significant adjustments in financial forecasts indicate serious deficiencies in the company's internal financial accounting and risk control mechanisms, which could undermine investor confidence and create uncertainties for future financing and operations [1][2] Group 2 - The challenges faced by Tonghua Dongbao are not solely due to accounting practices but also stem from a disconnect between strategic execution and industry changes, particularly in response to price pressures from medical insurance procurement [2] - Despite adopting a strategy of exchanging price for volume, the company has not seen significant improvements in sales revenue and profits, indicating weaknesses in pricing, channel management, and market expansion capabilities [2] - In contrast, competitors like Ganli Pharmaceutical have managed to achieve revenue and profit growth under similar procurement conditions, highlighting the disparities in product competitiveness, brand influence, cost control, and internal governance between companies [2]

大家早上壕！ 先看海外要闻： 上周五，美股盘中特朗普提及关税后，标普、纳指一度回吐过半涨幅、道指曾跌超百点。最终道指涨0.05%，标普500指数涨0.74%，纳斯达克涨 1.26%。 英伟达收涨超4%，特斯拉大涨近10%、一周涨18%，谷歌盘初涨超4%后回吐多数涨幅。中概指数止步三连涨，但全周涨超7%。 美债收益率连日下行。美元反弹，一个多月来首次周度上涨。 黄金回落超1%、全周转跌，对等关税宣布以来首次周度下跌。原油两日反弹，但美油一周跌超2%。 知名分析师：苹果将销美iPhone全搬到印度组装不切实际。 美国农业部：中国取消了1.2万吨美国猪肉订单，较前一周大幅减少72%。中国近期仅采购了1800吨大豆，远低于截至4月10日当周的采购量7.3万 吨。 国内重大事件汇总： 1、中共中央政治局4月25日下午就加强人工智能发展和监管进行第二十次集体学习。（新华社） 12、2025年国内核电项目审批首次开闸：国常会核准10台新机组，拉动超2000亿投资。我国首个核电工业操作系统发布，将在华龙一号新机组全 面应用。国家原子能机构：正组织编制全口径核技术应用产业中长期发展规划。国家核安全局局长董保同：我国核电已进入大 ...

Group 1: Nuclear Power Projects - The State Council approved 10 new nuclear power units, including projects in Guangxi, Guangdong, Zhejiang, Shandong, and Fujian, with a total investment exceeding 200 billion yuan [1] Group 2: Cross-Border E-Commerce - The State Council approved the establishment of cross-border e-commerce comprehensive pilot zones in 15 cities, including Hainan and Qinhuangdao, to enhance the e-commerce statistical system and provide tax exemptions for retail exports [2] Group 3: Information Disclosure Regulations - The China Securities Regulatory Commission (CSRC) issued new regulations for information disclosure exemptions, allowing companies to use aliases or summarize information to mitigate disclosure risks [3] Group 4: Tax Policy Adjustments - The Ministry of Commerce and other departments announced a reduction in the threshold for tax refunds for departing travelers, allowing refunds for purchases over 200 yuan [4] Group 5: Housing Loan Tax Deductions - The State Taxation Administration clarified that taxpayers can continue to enjoy tax deductions on housing loan interest when replacing existing loans for the same property [5] Group 6: Smart Manufacturing Guidelines - The Ministry of Industry and Information Technology released guidelines outlining 40 typical scenarios for smart manufacturing, aimed at fostering the development of smart factories and manufacturing standards [6] Group 7: Trade Fair Participation - The 137th Canton Fair saw over 224,000 foreign buyers attending, marking a record high for the event [7] Group 8: Artificial Intelligence Industry - China has established a complete artificial intelligence industry system, with over 1.57 million patent applications, accounting for 38.58% of the global total [8] Group 9: Low Altitude Economy - The low altitude airspace management may be gradually delegated to prefecture-level cities, with expectations for eVTOL commercial operations in major cities by 2027 [9] Group 10: Tax Refund Pilot in Shenzhen - Shenzhen launched a "one order, one package" pilot for tax refunds, enhancing convenience for travelers [10] Group 11: Company News - Stock Warnings - Songfa Co. and Chuan Da Zhisheng will face delisting risk warnings due to negative net profits and revenues below 300 million yuan [11][12] - *ST Gongzhi may face termination of listing due to audit issues, with stock suspension starting April 28 [13] - *ST Renle revised its performance forecast, indicating a potential negative net asset situation [14] Group 12: Company Performance Reports - Jinli Yongci reported a 57.85% increase in net profit for Q1 2025, with plans to repurchase shares worth 100 million to 200 million yuan [15][16] - Tianyuan Environmental reported an 88.61% increase in net profit for Q1 2025, also planning a share repurchase [17] - Taihe Intelligent reported a 716.41% increase in net profit for Q1 2025 [18] - Tonghua Dongbao revised its 2024 profit forecast to a loss of approximately 42.72 million yuan [19] - Jinchuan Group plans to sell assets worth 1.03 billion yuan to optimize its asset structure [20] - Teruid announced it is the first candidate for a procurement project worth 5.63 billion yuan [21] - Sunshine Power reported a 100% increase in wind power converter shipments in Q1 2025, indicating strong growth in the wind energy sector [22] - Shiyao Holdings plans to invest up to 787 million yuan in a new drug research and development base [23] - Jiaze New Energy received approval for 350 MW wind power projects [24]

// 今日关注 // // 宏观预警 // 1、十四届全国人大常委会第十五次会议审议民营经济促进法草案等 十四届全国人大常委会第十五次会议27日上午在京举行第一次全体会议。会议听取了全国人大宪法法律 委主任委员信春鹰作的关于民营经济促进法草案审议结果的报告。草案三审稿进一步充实支持民营经济 发展相关举措，进一步规范执法行为，加强劳动者合法权益保护，优化民营经济健康发展、高质量发展 的法治环境。 2、国务院常务会议讨论并原则通过《中华人民共和国医疗保障法（草案）》 国务院总理李强4月27日主持召开国务院常务会议，讨论并原则通过《中华人民共和国医疗保障法（草 案）》，决定将草案提请全国人大常委会审议。会议指出，要以此次立法为契机，进一步完善我国医疗 保障政策体系，有效保护参保人合法权益，打牢人民群众病有所医的制度基础。要加强医保基金监管， 健全监督检查机制，严厉打击虚假诊疗、虚假购药等欺诈骗保行为。要加强普法宣传教育，提升医疗机 构、医务人员和群众守法意识，规范就医秩序和医疗行为。 3、最高法：坚决防止把经济纠纷当作犯罪处理 最高法近日印发关于坚持严格公正司法规范涉企案件审判执行工作的通知，积极促进法治化营商环境 ...

证券代码：600867 证券简称：通化东宝 公告编号：2025-023 通化东宝药业股份有限公司 2024 年年度业绩预告更正公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 业绩预告的具体适用情形：净利润为负值。 通化东宝药业股份有限公司（以下简称"公司"）预计 2024 年年度实现 归属于上市公司股东的净利润约为-4,272.32 万元，与上年同期相比，将减少约 121,055.85 万元，同比减少约 103.66%。 预计 2024 年度实现归属于上市公司股东的扣除非经常性损益后的净利 润约为-919.54 万元，与上年同期相比，将减少约 117,670.86 万元，同比减少约 100.79%。 一、本期业绩预告情况 （一）业绩预告期间 103.66%。预计 2024 年度实现归属于上市公司股东的扣除非经常性损益后的净利 润约为-919.54 万元，与上年同期相比，将减少约 117,670.86 万元，同比减少约 100.79%。 二、上年同期经营业绩和财务状况情况 （一）2023 年年度，利润总额 ...

Financial Performance - The company expects a net profit attributable to shareholders of approximately 11.64 million yuan for 2024, a decrease of about 115.62 million yuan or 99.00% compared to the previous year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is estimated to be around 26.35 million yuan, a decrease of approximately 90.40 million yuan or 77.43% year-on-year[2]. - In 2023, the total profit was 136.59 million yuan, with a net profit attributable to shareholders of 116.78 million yuan[3]. Legal Issues - The company faced a legal ruling requiring compensation of approximately 61.31 million yuan due to trademark infringement, which significantly impacted the financial outlook[5]. - The company had previously estimated the compensation amount to be around 30 million yuan before receiving the final court ruling[5]. - The company has ceased production of the "Changshulin" insulin and has adopted a new brand "Pingshulun," mitigating potential impacts from the legal ruling[7]. Forecasting and Communication - The board of directors expressed sincere apologies for the discrepancies in the earnings forecast and committed to improving the accuracy of future forecasts[7]. - The revised earnings forecast is based on preliminary calculations, and the final audited financial data will be disclosed in the annual report[6]. - The company emphasizes the importance of cautious communication with auditors to enhance the scientific basis of performance predictions[7]. - Investors are advised to pay attention to investment risks associated with the revised earnings forecast[6].

Core Viewpoint - Tonghua Dongbao (600867) has revised its 2024 annual performance forecast, expecting a significant decline in net profit attributable to shareholders, indicating potential financial distress for the company [1] Financial Performance Summary - The company anticipates a net profit of approximately -42.72 million yuan for 2024, representing a year-on-year decrease of about 103.66% [1] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be around -9.19 million yuan, reflecting a year-on-year decline of approximately 100.79% [1] - Previously, the company had estimated a net profit of about 116.42 million yuan for 2024, with a forecasted net profit of approximately 264 million yuan after excluding non-recurring items [1]

Market Performance - The recombinant protein sector declined by 1.56%, ranking among the top losers in concept sectors as of April 25 [1][2] - Notable stocks within the sector that hit the daily limit down include Jiangsu Wuzhong and Weiming Pharmaceutical, while stocks like HJ Bio, Wanfang Development, and Aladdin saw significant declines [1] Top Gainers and Losers - Among the top gainers in the recombinant protein sector, Borui Pharmaceutical, BeiDa Pharmaceutical, and Tonghua Dongbao increased by 4.39%, 2.42%, and 2.31% respectively [1] - The sector experienced a net outflow of 158 million yuan, with 22 stocks seeing net outflows, and five stocks exceeding 10 million yuan in outflows [2] Capital Flow Analysis - The stock with the highest net outflow was Xilong Science, with a net outflow of 190 million yuan, followed by Furida and Dezhan Health with outflows of 19.41 million yuan and 19.18 million yuan respectively [2][3] - Conversely, the stocks with the highest net inflows included Zhongyuan Qihua, Zhifei Biological, and Chengdu Xian Dao, with inflows of 26.63 million yuan, 25.06 million yuan, and 17.51 million yuan respectively [2][3]

Investment Rating - The report indicates a positive outlook for the weight loss drug sector within the pharmaceutical and biotechnology industry, suggesting potential acceleration in business development (BD) opportunities [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a slight decline of -0.36% from April 14 to April 18, underperforming compared to the Wind All A index (0.39%) and the CSI 300 index (0.59). The market showed a preference for defensive sectors, with chemical preparations (0.62%), traditional Chinese medicine (0.6%), and offline pharmacies (0.19%) showing minor gains, while blood products (-4.39%), other biological products (-1.78%), and vaccines (-1.49%) saw significant pullbacks [2][7]. - The GLP-1 receptor agonists are expected to catalyze growth in the weight loss drug sector. Notably, Eli Lilly announced positive results from the Phase III ACHIEVE-1 study for its oral drug Orforglipron, which is set to expand the application of GLP-1 drugs. This class of drugs is becoming a focal point for multinational corporations (MNCs) in the metabolic disease space, with domestic companies poised to benefit from rapid innovation and lower R&D costs [2][12]. Market Weekly Review - The pharmaceutical and biotechnology sector's performance from April 14 to April 18 showed a decline of -0.36%, with the market favoring defensive stocks. The top gainers included Shuangcheng Pharmaceutical (56.4%), Kangpeng Technology (56.3%), and Lifang Pharmaceutical (47.1%), while the largest losers were *ST Jiyuan (-50.7%), Hasanlian (-19.1%), and Changyao Holdings (-18.5%) [7][10]. Industry News and Key Company Announcements - On April 17, Eli Lilly announced that its oral GLP-1 receptor agonist Orforglipron achieved positive results in its Phase III study, showing significant reductions in A1C levels and weight loss compared to placebo [12]. - Pfizer terminated the development of its GLP-1 small molecule receptor agonist Danuglipron due to potential liver damage in trial participants [12]. - The report highlights several companies making strides in the industry, including the approval of new indications for Merck's Gardasil 9 HPV vaccine and the progress of various clinical trials for innovative drugs [13][14].